Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) with Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis

Project: Research project

Project Details

Description

Pending
StatusFinished
Effective start/end date7/1/1412/31/18

Funding

  • Icahn School of Medicine at Mount Sinai (0254-7378-4605///5P01CA108671-08)
  • National Cancer Institute (0254-7378-4605///5P01CA108671-08)

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.